1. A 65-year-old male presents with painless lymphadenopathy and night sweats. A lymph node biopsy reveals a diffuse proliferation of large B cells with a high mitotic index. Which translocation is most likely associated with this condition?
2. A patient with B cell lymphoma has a flow cytometry report showing CD19+, CD20+, CD10+, and BCL6+ markers. What is the most likely diagnosis?
3. A 45-year-old female with a history of Sjogren’s syndrome presents with a mass in the parotid gland. Biopsy shows lymphoepithelial lesions with malignant B cells. What type of lymphoma is this indicative of?
4. Which subtype of B cell lymphoma is characterized by the translocation t(11;14) leading to overexpression of cyclin D1?
5. A patient with B cell lymphoma is found to have BCL2 gene rearrangement. Which histological subtype of lymphoma is this finding most consistent with?
6. Which of the following markers is least likely to be expressed in mantle cell lymphoma: CD5, CD20, Cyclin D1, or CD10?
7. A 50-year-old male presents with fatigue and splenomegaly. Peripheral blood smear shows circulating villous lymphocytes. What is the most likely diagnosis?
8. In a patient with Burkitt lymphoma, which virus is most commonly associated with the endemic form of this disease?
9. A patient with chronic lymphocytic leukemia (CLL) develops large cell lymphoma. What is this transformation called?
10. What is the most common site of extranodal involvement in MALT lymphoma?
11. A patient with follicular lymphoma has a waxing and waning course of disease. Which translocation involving the BCL2 gene is commonly associated with this type of lymphoma?
12. Which chemotherapeutic regimen is most commonly used as first-line treatment for diffuse large B cell lymphoma?
13. What immunophenotypic markers are characteristic of hairy cell leukemia?
14. Which subtype of B cell lymphoma is characterized by starry sky appearance on histopathology?
15. What is the role of rituximab in the treatment of B cell lymphomas?
16. Which subtype of B cell lymphoma is most likely to involve the central nervous system at presentation?
17. What genetic mutation is most commonly associated with Waldenström macroglobulinemia?
18. In the staging of B cell lymphomas, what does the “B” in “Stage IIIB” indicate?
19. What is the typical clinical presentation of primary mediastinal B cell lymphoma?
20. How does the MYC gene rearrangement influence the prognosis of diffuse large B cell lymphoma?
21. What is the significance of the Ki-67 proliferation index in B cell lymphomas?
22. Which subtype of B cell lymphoma is associated with a fish flesh appearance on gross examination of the tumor?
23. What role does the Epstein-Barr virus play in the pathogenesis of Hodgkin lymphoma?
24. What is the mechanism of action of ibrutinib in the treatment of mantle cell lymphoma?
25. How does the presence of t(14;18) translocation influence the treatment strategy for follicular lymphoma?
26. What is the role of autologous stem cell transplantation in the management of relapsed/refractory B cell lymphomas?
27. In the context of lymphoma staging, what does Ann Arbor Stage III indicate?
28. Which subtype of B cell lymphoma is most commonly associated with the gastrointestinal tract?
29. What is the typical presentation and prognosis of primary effusion lymphoma?
30. What is the significance of CD30 expression in the diagnosis of anaplastic large cell lymphoma?
31. How does the presence of double-hit or triple-hit lymphoma affect treatment outcomes?
32. What are the diagnostic criteria for Richter’s transformation in patients with chronic lymphocytic leukemia?
33. What is the significance of bone marrow involvement in the prognosis of B cell lymphomas?
34. How is central nervous system prophylaxis typically administered in patients with high-risk B cell lymphomas?
35. What is the role of PET-CT in the staging and response assessment of B cell lymphomas?
36. How does the International Prognostic Index (IPI) influence treatment decisions in diffuse large B cell lymphoma?
37. What is the mechanism of action of bortezomib in the treatment of multiple myeloma and mantle cell lymphoma?
38. What is the clinical significance of lactate dehydrogenase (LDH) levels in patients with B cell lymphomas?
39. How does the presence of bulky disease influence the staging and treatment of B cell lymphomas?
40. What are the most common side effects associated with the use of rituximab in B cell lymphomas?
41. What is the role of lenalidomide in the treatment of relapsed/refractory follicular lymphoma?
42. How does the expression of CD5 help differentiate between chronic lymphocytic leukemia and mantle cell lymphoma?
43. What is the significance of NOTCH1 mutations in the prognosis of chronic lymphocytic leukemia?
44. How does the presence of a MYD88 L265P mutation influence the diagnosis and treatment of Waldenström macroglobulinemia?
45. What are the indications for initiating treatment in asymptomatic patients with chronic lymphocytic leukemia?
46. How does the presence of del(17p) influence the prognosis and treatment of chronic lymphocytic leukemia?
47. What is the typical presentation of primary cutaneous B cell lymphoma, and how is it managed?
48. How does the use of checkpoint inhibitors impact the treatment of relapsed/refractory Hodgkin lymphoma?
49. What is the mechanism of action of CAR T-cell therapy in the treatment of B cell lymphomas?
50. What are the criteria for diagnosing post-transplant lymphoproliferative disorder (PTLD) in organ transplant recipients?
51. How does the presence of B symptoms influence the staging and prognosis of B cell lymphomas?
52. What is the significance of t(8;14) translocation in the diagnosis of Burkitt lymphoma?
53. How is tumor lysis syndrome managed in patients undergoing treatment for aggressive B cell lymphomas?
54. What are the characteristic features of splenic marginal zone lymphoma, and how is it diagnosed?
55. How does the expression of CD23 help differentiate between chronic lymphocytic leukemia and other B cell lymphomas?
56. What is the role of bendamustine in the treatment of indolent B cell lymphomas?
57. How does the presence of a PAX5 gene rearrangement influence the diagnosis and treatment of B cell lymphomas?
58. What are the common presenting symptoms of primary central nervous system lymphoma?
59. How is histologic transformation of indolent B cell lymphomas diagnosed and managed?
60. What is the role of maintenance therapy in the management of follicular lymphoma?
61. How does the presence of extranodal involvement influence the prognosis of B cell lymphomas?
62. What are the clinical and histologic features of nodal marginal zone lymphoma?
63. How is mantle cell lymphoma typically staged and what is the significance of each stage?
64. What is the significance of TP53 mutations in the prognosis of chronic lymphocytic leukemia?
65. How is treatment response typically assessed in patients with B cell lymphomas?
66. What are the common side effects of proteasome inhibitors in the treatment of B cell lymphomas?
67. How does the expression of CD38 and ZAP-70 influence the prognosis of chronic lymphocytic leukemia?
68. What is the role of high-dose methotrexate in the treatment of primary central nervous system lymphoma?
69. How is primary mediastinal B cell lymphoma typically managed, and what are the treatment options?
70. What is the significance of IgVH mutational status in the prognosis of chronic lymphocytic leukemia?
71. How does the expression of MUM1 help differentiate between subtypes of B cell lymphomas?
72. What is the typical presentation and treatment of primary bone lymphoma?
73. How does the presence of Epstein-Barr virus influence the pathogenesis and prognosis of Burkitt lymphoma?
74. What is the role of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma?
75. How is the diagnosis of lymphoplasmacytic lymphoma confirmed, and what are the treatment options?
76. What are the common features of primary testicular lymphoma, and how is it managed?
77. How does the presence of t(3;14) translocation influence the diagnosis and treatment of B cell lymphomas?
78. What is the significance of beta-2 microglobulin levels in the prognosis of B cell lymphomas?
79. How does the presence of p53 mutations affect the treatment and prognosis of B cell lymphomas?
80. What is the role of allogeneic stem cell transplantation in the treatment of relapsed/refractory B cell lymphomas?
81. How is primary gastric lymphoma typically diagnosed and managed?
82. What are the clinical and pathologic features of primary hepatic lymphoma?
83. How does the presence of MYC, BCL2, and BCL6 rearrangements influence the prognosis of B cell lymphomas?
84. What is the role of maintenance rituximab in the treatment of B cell lymphomas?
85. How is the diagnosis of chronic lymphocytic leukemia confirmed, and what are the treatment options?
86. What is the significance of SOX11 expression in the diagnosis of mantle cell lymphoma?